Drug Profile

CVI HBV 002

Alternative Names: CVI-HBV-002

Latest Information Update: 28 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cha Vaccine Institute
Class Hepatitis B vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Hepatitis B

Most Recent Events

28 Sep 2024 No recent reports of development identified for phase-I development in Hepatitis-B(Prevention) in South Korea (IM, Injection)
04 Dec 2023 CHA Vaccine Institute completes a phase II trial in Hepatitis B (Treatment-experienced) in South Korea (IM) (NCT04289987)
01 Dec 2023 Pharmacodynamic data from the preclinical studies on CVI HBV 002 in Hepatitis B released by CHA Vaccine Institute (CHA Vaccine Institute website, December 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com